Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control.

Eduardo García, Pedro Gil, Inka Miñambres, Aleyda Benitez-Amaro, Claudia Rodríguez, Lene Claudi, Josep Julve, Sonia Benitez, Jose Luís Sánchez-Quesada, Jose Rives, Xavier Garcia-Moll, David Vilades, Antonio Perez, Vicenta Llorente-Cortes

Journal: Frontiers in endocrinology 2023;14():1236487

PMID: 37635956

Abstract

BACKGROUND

Low-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism.

OBJECTIVES

To evaluate soluble LRP1 (sLRP1) and ANP levels in people with newly diagnosed type 2 diabetes mellitus (T2DM) and determine the effects of metabolic optimization.

METHODS

This single-center longitudinal observational study recruited patients with newly diagnosed T2DM ( = 29, HbA1c > 8.5%), and 12 healthy control, age- and sex-matched volunteers. sLRP1 and ANP levels were measured by immunoassays at T2DM onset and at one year after optimization of glycemic control (HbA1c ≤ 6.5%).

RESULTS

T2DM had higher sLRP1 levels than the control group (p = 0.014) and lower ANP levels (p =0.002). At 12 months, 23 T2DM patients reached the target of HbA1c ≤ 6.5%. These patients significantly reduced sLRP1 and increased ANP levels. Patients who did not achieve HbA1c < 6.5% failed to normalize sLRP1 and ANP levels. There was an inverse correlation in the changes in sLRP1 and ANP (p = 0.031). The extent of sLRP1 changes over 12 months of metabolic control positively correlated with those of total cholesterol, LDL cholesterol, TG, TG/HDLc, and apolipoprotein B.

CONCLUSIONS

Newly diagnosed T2DM patients have an increased sLRP1/ANP ratio, and increased sLRP1 and decreased ANP levels are normalized in the T2DM patients that reached an strict glycemic and metabolic control. sLRP1/ANP ratio could be a reliable marker of cardiometabolic function.

Copyright © 2023 García, Gil, Miñambres, Benitez-Amaro, Rodríguez, Claudi, Julve, Benitez, Sánchez-Quesada, Rives, Garcia-Moll, Vilades, Perez and Llorente-Cortes.

Address: Institut de Recerca de l'Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain.; Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain.; Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain.; Universitat Autònoma de Barcelona, Barcelona, Spain.; Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.; Cardiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain.; Cardiac Imaging Unit, Cardiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.